NASDAQ: ACOGAlpha Cognition Inc Stock
$5.44-0.19 (-3.37%)
Updated Mar 14, 2025
ACOG Price
$5.44
Fair Value Price
N/A
Market Cap
$84.49M
52 Week Low
$4.66
52 Week High
$7.00
P/E
N/A
P/B
-28.94x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.72
Operating Cash Flow
N/A
Beta
0.23
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACOG Overview
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACOG's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ACOG
Ranked#112 of 484
Ranked#112 of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.84 | A | |
| $137.96 | A | |
| $8.16 | A |
Be the first to know about important ACOG news, forecast changes, insider trades & much more!
ACOG News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACOG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACOG's short-term assets ($4.51M) exceed its short-term liabilities ($3.01M)
Short-term Liabilities Financials
ACOG's long-term liabilities ($4.94M) exceed its short-term assets ($4.51M)
Long-term Liabilities Financials
ACOG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more ACOG due diligence checks available for Premium users.
Valuation
ACOG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-28.94x
Industry
4.68x
ACOG's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
Assets to liabilities
Assets
$5.0M
Liabilities
$7.9M
Debt to equity
-2.72
ACOG's short-term assets ($4.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACOG's long-term liabilities ($4.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACOG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ACOG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
$0.0
Financing
$4.2M
ACOG vs Biotech Stocks
Alpha Cognition Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.